CAS 1672668-24-4: Belzutifan

Description:Belzutifan, also known by its developmental code name, is a small molecule inhibitor that targets hypoxia-inducible factor 2 alpha (HIF-2α), a transcription factor involved in the regulation of various genes related to cellular response to low oxygen levels. This compound is characterized by its ability to disrupt the HIF-2α pathway, which is often overactive in certain cancers, particularly renal cell carcinoma. By inhibiting this pathway, Belzutifan aims to reduce tumor growth and improve patient outcomes. The substance is typically administered orally and has been studied for its efficacy in treating specific malignancies. Its chemical structure includes various functional groups that contribute to its pharmacological properties, including solubility and bioavailability. Belzutifan has undergone clinical trials to evaluate its safety and effectiveness, and it has received regulatory approval for use in certain indications. As with many targeted therapies, its use may be accompanied by specific side effects, necessitating careful monitoring during treatment.

Found 4 products.

Product data	Purity	Price range	Estimated delivery
PT2977 REF: IN-DA01V3M7CAS: 1672668-24-4	98%	To inquire	Thu 27 Mar 25
Belzutifan REF: 4Z-B-263001CAS: 1672668-24-4	- - -	To inquire	Fri 28 Mar 25
Belzutifan REF: TM-T16679CAS: 1672668-24-4	99.34% - 99.41%	70.00 €~1,264.00 €	Thu 03 Apr 25
PT2977 REF: 3D-XRC66824CAS: 1672668-24-4	Min. 95%	664.00 €~4,080.00 €	Thu 22 May 25